Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Ile-Cys-Phe)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004291 AN007135 Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatment Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003565 AN005857 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003179 AN005221 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001175 AN001950 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
  logo